Law360, New York (October 12, 2009, 6:00 PM ET) -- Teva Pharmaceutical Industries Ltd. has struck back with patent invalidity counterclaims against rival Gilead Sciences Inc. in an infringement case involving drug treatments for HIV.
On Friday, Teva filed a second amended answer and counterclaim to the suit Gilead brought against the company in the U.S. District Court for the Southern District of New York.
In a second amended complaint, Gilead accused Teva of infringing patents for Truvada, tablets containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, and for Atripla, which is...
Teva Hits Back In Gilead Patent Suit Over HIV Drug
To view the full article, take a free trial now.
